openPR Logo
Press release

Chemotherapy Induced Anemia Therapeutics Market Size in the 7MM is expected to Grow by 2032, estimates DelveInsight

01-20-2025 11:12 PM CET | Health & Medicine

Press release from: ABNewswire

Chemotherapy Induced Anemia Therapeutics Market Size in the 7MM

DelveInsight's 'Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Chemotherapy Induced Anemia in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Unlock key insights into the Chemotherapy Induced Anemia Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Chemotherapy Induced Anemia Market Size [https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chemotherapy Induced Anemia Market Report

* According to DelveInsight's analysis, in Spain study of 349 patients with lung cancer, 64 already had anemia before starting chemotherapy. Among the 285 patients with normal hemoglobin (Hb) levels at baseline, 80.7% (n = 230) developed anemia. Of these, 49.1% experienced mild anemia, 25.6% had moderate anemia, and 6% suffered from severe anemia.
* Our analysis reveals that in the US around 90% of non-Hodgkin lymphoma patients develop CIA during their first chemotherapy cycle. The incidence proportions for CIA grades were 58.9%, 28.2%, 11.2%, and 1.8% for grades 1, 2, 3, and 4, respectively. In terms of morphology, 90% of CIAs were normocytic, 6% were macrocytic, and 4% were microcytic, with 53% being normochromic, 41% hyperchromic, and 6% hypochromic.
* The leading Chemotherapy Induced Anemia Companies such as Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus, Cadila and others.
* Promising Chemotherapy Induced Anemia Therapies such as Roxadustat, Desidustat, SEPO Registered , Epoetin alfa, peginesatide, epoetin beta, r-HuEPO, Aranesp, Gilteritinib , and others

Stay ahead in the competitive landscape of the Chemotherapy Induced Anemia Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Chemotherapy Induced Anemia Treatment Market Size [https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chemotherapy Induced Anemia Epidemiology Segmentation in the 7MM

* Chemotherapy Induced Anemia Incident Cases
* Chemotherapy Induced Anemia Severity-Specific Incident Cases
* Chemotherapy Induced Anemia Treatable Cases

Download the report to understand which factors are driving Chemotherapy Induced Anemia epidemiology trends @ Chemotherapy Induced Anemia Prevalence [https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chemotherapy Induced Anemia Therapeutics Market

"The current market for CIA remains underdeveloped, with a lack of new drugs and limited approved therapies. This gap has made biosimilar a key driver of market expansion, offering affordable alternatives to existing medications. As new drug development remains slow, biosimilar are increasingly filling the void, providing accessible treatment options and contributing to market growth by reducing costs for both healthcare providers and patients."

Chemotherapy Induced Anemia Treatment Market

Anemia is a frequent but insidious complication of cancer and its cytotoxic chemotherapy. According to the World Health Organization (WHO) definition, anemia occurs when hemoglobin (Hb) levels drop below 12 g/dL for women and 13 g/dL for men, and severity ranges from mild to severe or life-threatening. Anemia contributes to debilitating fatigue, lethargy, cardiovascular problems, shortness of breath, and reduced cognitive function in individuals who often already have significant morbidity and diminished quality of life (QOL) due to their malignancy.

Discover the future of Chemotherapy Induced Anemia treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Chemotherapy Induced Anemia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chemotherapy Induced Anemia Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Chemotherapy Induced Anemia Companies- Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus, Cadila and others.
* Chemotherapy Induced Anemia Therapies- Roxadustat, Desidustat, SEPO Registered , Epoetin alfa, peginesatide, epoetin beta, r-HuEPO, Aranesp, Gilteritinib , and others
* Chemotherapy Induced Anemia Therapeutic Assessment: Chemotherapy Induced Anemia Current Marketed and Chemotherapy Induced Anemia Emerging Therapies
* Chemotherapy Induced Anemia Market Dynamics: Chemotherapy Induced Anemia market drivers and Chemotherapy Induced Anemia market barriers
* Chemotherapy Induced Anemia Unmet Needs, KOL's views, Analyst's views, Chemotherapy Induced Anemia Market Access and Reimbursement

Explore the dynamics of the Chemotherapy Induced Anemia Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Chemotherapy Induced Anemia Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Chemotherapy Induced Anemia Overview at a Glance

4. Chemotherapy Induced Anemia Overview at a Glance

5. Chemotherapy Induced Anemia Executive Summary

6. Disease Background and Overview

7. Chemotherapy Induced Anemia Epidemiology and Patient Population

8. Japan

9. Patient Journey

10. Chemotherapy Induced Anemia Emerging Drugs

11. Other Assets

12. Chemotherapy Induced Anemia: 7 Major Market Analysis

13. Chemotherapy Induced Anemia KOL Views

14. Chemotherapy Induced Anemia SWOT

15. Chemotherapy Induced Anemia Unmet Needs

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chemotherapy-induced-anemia-therapeutics-market-size-in-the-7mm-is-expected-to-grow-by-2032-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chemotherapy Induced Anemia Therapeutics Market Size in the 7MM is expected to Grow by 2032, estimates DelveInsight here

News-ID: 3823720 • Views:

More Releases from ABNewswire

Alcohol Use Disorder Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Alkermes, Teva Pharma, BioCorRx, Inc., Adial Pharma, ADDEX THERAPEUTICS
Alcohol Use Disorder Pipeline 2026: Latest FDA Approvals, Clinical Trials, and E …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Alcohol Use Disorder pipeline constitutes 30+ key companies continuously working towards developing 30+ Alcohol Use Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Alcohol Use Disorder Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alcohol Use Disorder Market. The
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 - DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by …
The Key Muscle Invasive Bladder Cancer Companies in the market include - CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics, Binhui Biopharmaceutical, SURGE Therapeutics, Pfizer, AstraZeneca, ImmunityBio, Inc., Guarionex J. Decastro, Janssen Research & Development, Tollys, Aura Biosciences, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, BristolMyers Squibb, Asieris Pharmaceuticals, and others. DelveInsight's "Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth
Curiva Med Spa Unveils XERF Technology in Beverly Hills, California: A New Era of Non-Invasive Aesthetic Medicine
Curiva Med Spa Unveils XERF Technology in Beverly Hills, California: A New Era o …
Curiva Med Spa in Beverly Hills debuts XERF, a zero-downtime lifting tech, partnering with Cynosure Lutronic. Led by Tamara Yang DNP and Amar Hirani MBA, the clinic combines Ivy League medical rigor with luxury hospitality. With an expert nursing team and Visia 7 data-driven analysis, this sanctuary at the Beverly Hills Plaza Hotel has organically built a loyal following including celebrities and influencers. BEVERLY HILLS, Calif. - Partnering with global leader
Playwise HQ Launches HubSpot Integration to Sync Deals and Competitive Win/Loss Insights
Playwise HQ Launches HubSpot Integration to Sync Deals and Competitive Win/Loss …
Playwise HQ has launched a HubSpot CRM integration that syncs Deals and win/loss outcomes between HubSpot and Playwise HQ. Sales teams can capture primary and secondary win/loss reasons, detailed deal feedback, and competitor-specific insights directly from closed opportunities. This ensures competitor battlecards show a complete history of deals won and lost, helping reps identify patterns, improve positioning, and keep competitive intelligence consistent across both platforms. SYDNEY, Australia - 19 February, 2026

All 5 Releases


More Releases for Anemia

Chemotherapy-Induced Anemia Market Forecast by Type Mild Moderate Severe and Lif …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Chemotherapy-Induced Anemia Market- (By Type of Anemia (Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia), By Treatment Type (RBC Transfusion, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp Injection, Epoetin Alfa Injection, and Others), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)), By Region, Trends, Industry Competition
Rising Cancer And Anemia Cases Propel Growth In Chemotherapy-Induced Anemia Mark …
The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Chemotherapy-Induced Anemia Market Size During the Forecast Period? The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, …
As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Iron Deficiency Anemia in the 7MM. DelveInsight's "Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size,
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435 This latest report researches the industry structure,
Anemia Drugs Market 2018 Grow at CAGR of 8.4% to Reach USD 34.7 Billion | By Uni …
Market Research Future Published a Prime research Report on “Global Anemia Drugs Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022 Global Anemia Drugs Market - Segments Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration;
Anemia in Chronic Kidney Disease (Renal Anemia) - Industry Analysis, Trends, and …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Anemia in Chronic Kidney Disease Pipeline Review, H1 2017” to its report offerings. The report provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196648 Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017,